BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8777171)

  • 1. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.
    Bierman PJ; Anderson JR; Freeman MB; Vose JM; Kessinger A; Bishop MR; Armitage JO
    Ann Oncol; 1996 Feb; 7(2):151-6. PubMed ID: 8777171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
    Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
    Reece DE; Barnett MJ; Shepherd JD; Hogge DE; Klasa RJ; Nantel SH; Sutherland HJ; Klingemann HG; Fairey RN; Voss NJ
    Blood; 1995 Jul; 86(2):451-6. PubMed ID: 7541661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
    Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
    Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
    Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
    Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease.
    Kessinger A; Bierman PJ; Vose JM; Armitage JO
    Blood; 1991 Jun; 77(11):2322-5. PubMed ID: 1674890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
    Schmitz N; Glass B; Dreger P; Haferlach T; Horst HA; Ollech-Chwoyka J; Suttorp M; Gassmann W; Löffler H
    Ann Hematol; 1993 May; 66(5):251-6. PubMed ID: 8099502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Dicke KA; Armitage JO; Cabanillas FF; Horwitz LJ; Vellekoop L; Zander AR; Spitzer G
    Ann Intern Med; 1986 Feb; 104(2):163-8. PubMed ID: 3511811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
    Stuart MJ; Chao NS; Horning SJ; Wong RM; Negrin RS; Johnston LJ; Shizuru JA; Long GD; Blume KG; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2001; 7(10):552-60. PubMed ID: 11760087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
    Villa D; Seshadri T; Puig N; Massey C; Tsang R; Keating A; Crump M; Kuruvilla J
    Haematologica; 2012 May; 97(5):751-7. PubMed ID: 22180434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE; Phillips GL
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support.
    Hurd DD; Haake RJ; Lasky LC; Christiansen NP; McGlave PB; Bostrom B; Levine EG; Weisdorf DJ; Kim TH; Peterson BA
    Med Pediatr Oncol; 1990; 18(6):447-53. PubMed ID: 1978232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
    Argiris A; Seropian S; Cooper DL
    Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy.
    Reece DE; Connors JM; Spinelli JJ; Barnett MJ; Fairey RN; Klingemann HG; Nantel SH; O'Reilly S; Shepherd JD; Sutherland HJ
    Blood; 1994 Mar; 83(5):1193-9. PubMed ID: 8118023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Spinolo JA; Jagannath S; Velásquez W; Spitzer G; Cabanillas F; Hagemeister F; Horwitz LJ; Dicke KA
    Leuk Lymphoma; 1993 Jan; 9(1-2):71-7. PubMed ID: 8477204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.